0001493152-21-011025.txt : 20210511 0001493152-21-011025.hdr.sgml : 20210511 20210511161422 ACCESSION NUMBER: 0001493152-21-011025 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 6 CONFORMED PERIOD OF REPORT: 20210511 FILED AS OF DATE: 20210511 DATE AS OF CHANGE: 20210511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Biofrontera AG CENTRAL INDEX KEY: 0001712641 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: 2M FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38396 FILM NUMBER: 21911465 BUSINESS ADDRESS: STREET 1: HEMMELRATHER WEG 201 CITY: LEVERKUSEN STATE: 2M ZIP: D-51377 BUSINESS PHONE: 011 49 214 876 00 MAIL ADDRESS: STREET 1: HEMMELRATHER WEG 201 CITY: LEVERKUSEN STATE: 2M ZIP: D-51377 6-K 1 form6-k.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO

RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of May 2021

 

Commission File Number: 001-38396

 

BIOFRONTERA AG

(Registrant’s name / Translation of registrant’s name into English)

 

Hemmelrather Weg 201, D-51377 Leverkusen Germany

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [X] Form:40-F [  ]

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): N/A

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): N/A

 

 

 

 

 

 

EXHIBITS

 

Exhibit Number   Description
99.1  

Summary of the business performance in the first quarter 2021

99.2   Biofrontera reports Q1 2021 financial results

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  BIOFRONTERA AG
     
  By: /s/ Hermann Lübbert
  Name: Hermann Lübbert
  Title: Chief Executive Officer

 

Date: May 11, 2021

 

 
 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

Summary of the business performance in the first quarter 2021

 

Following initial pandemic-related an initial, pandemic-related slow start at the beginning of the year, Biofrontera’s business development in the first months of the year has been encouragingly positive since mid-March.

 

As expected, business activities and consequently sales continue to be strongly dependent on the development of the pandemic and the associated easing of lockdown regulations in our sales markets. The Company generated total sales of EUR 5,479 thousand in the first quarter of the year. Although this represents a decrease of 15% compared to EUR 6,473 thousand in the first quarter of 2020, the sales development over the months has since March been showing a very positive trend.

 

In the U.S., the Company generated revenues from product sales of EUR 3,811 thousand in the first quarter, compared to EUR 4,181 thousand in the same period of the prior year, a decrease of 9%. While sales in the U.S.A. in January and February 2021 were significantly lower than in the previous year due to the pandemic, sales in Germany in the first quarter remained relatively stable compared to the previous year. Here, sales improved by 7% to EUR 1,404 thousand compared to EUR 1,310 thousand in the first quarter of the previous year. In the rest of Europe, due to the pandemic sales decreased by 68% to EUR 265 thousand, compared to EUR 819 thousand in the first quarter of 2020.

 

The year-on-year sales recovery already perceived in mid-March 2021, especially in our key sales markets, continued in April 2021, indicating a significant recovery of the general pandemic situation in the U.S.A. as well as in Germany - probably also due to the continued vaccination effort. Also compared to 2019, i.e. monthly sales before the pandemic, the preliminary sales figures for April 2021 show an 8% increase in product sales in all markets. In this context, comparing April 2021 to April 2019, sales increased by 3% in the U.S., 25% in Germany, and 20% in the remaining European markets.

 

The U.S. offers tremendous growth potential for PDT with Ameluz®. The aim of Biofrontera’s commercial and clinical development strategy is to adapt and optimize the flagship product Ameluz® to market requirements and patient needs in the US market with the same discipline as has already been achieved in Europe. This will allow the Company to improve the market positioning, expand the market at the expense of the competitor drug and the predominantly used treatment option of cryotherapy, and ultimately to reach the next phase of the Company’s growth. For Xepi®, Biofrontera’s second product in its US portfolio, a marketing campaign is being prepared for the second half of 2021. The aim is to market Xepi® in the footsteps of the continued opening of dermatology practices for patient and sales force visits, with considerably greater effort than was possible in the pandemic year 2020.

 

Considerable progress was also made on the regulatory side in the first quarter of this year. In February and March, the company announced two submissions to the U.S. Food and Drug Administration (FDA) aimed at both enabling the simultaneous use of up to three tubes of Ameluz® by photodynamic therapy (PDT) and gaining approval for a larger lamp. As agreed with the FDA, a meeting is anticipated to be held in June for both submissions to discuss further procedures.

 

The capital increase, which was completed and fully placed in February 2021 with gross proceeds of EUR 24.7 million, was an important milestone in the first quarter. The issue of the new shares was received with great interest on both sides of the Atlantic, confirmed by a significant oversubscription, especially in the US capital market, after the completion of the capital measure. The proceeds from the capital measure will enable the company to further improve the market positioning of its flagship product Ameluz® in the future and to consistently pursue the Group’s medium-term strategy.

 

Ludwig Lutter has been appointed Chief Financial Officer (CFO) of Biofrontera AG as of March 2021, taking over from Thomas Schaffer. With Ludwig Lutter, the company was able to attract a leader with an international profile and impressive experience in growth companies to the Management Board. As a proven financial expert with extensive expertise in the US capital market, Mr. Lutter is uniquely qualified to further expand Biofrontera AG’s presence in the relevant US market. The change in the finance department took place within the framework of the already announced succession planning process by the Supervisory Board and Management Board.

 

Biofrontera AG Quarterly report Q1 2021 1
 

 

Key figures in accordance with IFRS

 

in EUR thousands  Jan 1 – Mar 31, 2021   Jan 1 – Mar 31, 2020 
   unaudited   unaudited 
Results of operations                
Sales revenue   5,479    100%   6,473    100%
Gross profit on sales   4,578    84%   5,674    88%
Result on operations   (4,089)   (75)%   (6,567)   (101)%
EBITDA   (3,158)   (58)%   (2,645)   (41)%
EBIT   (3,971)   (72)%   (5,555)   (86)%
Earnings (loss) before tax   (4,876)   (89)%   (5,498)   (85)%
Earning (loss) after tax   (4,877)   (89)%   (5,499)   (85)%

 

in EUR thousands  March 31, 2021   December 31, 2020 
   unaudited   unaudited 
Net assets        
Total assets   77,076    56,391 
Non-current assets   30,314    30,264 
Cash and cash equivalents   37,333    16,546 
Other current assets   9,429    9,580 
Non-current liabilites   40,005    40,730 
Current liabilities   11,438    8,286 
Equity   25,633    7,375 

 

   March 31, 2021   December 31, 2020 
   unaudited     
Number of employees   154    149 
           
Biofrontera Shares          
Number of shares outstanding 
   56,717,385    47,747,515 
Share price (Xetra closing price in EUR)   2.35    3.05 

 

Due to commercial rounding, rounding differences may occur in the tables.

 

Biofrontera AG Quarterly report Q1 2021 2
 

 

Biofrontera Group financial position and performance

 

Results of operations

 

Revenue

 

In the 1st quarter of 2021, a total of EUR 5,479 thousand in sales was generated, which represents a decrease of 15% compared to the previous year’s figure (EUR 6,473 thousand), whereby the ongoing COVID 19 pandemic significantly impacted the company’s business. The biggest impact was felt in the USA. In our largest sales market, we achieved product sales of EUR 3,811 thousand (prior-year period: EUR 4,181 thousand). This corresponds to a decline in sales of 9% compared to the first quarter of 2020. Sales in Germany improved to EUR 1,404 thousand compared to the first quarter of the previous year, which represents an increase of 7% (prior-year period: EUR 1,310 thousand). In other European countries, sales decreased by 68% compared to the prior-year period to EUR 265 thousand (prior-year period: EUR 819 thousand).

 

 

Gross profit on sales

 

Gross profit decreased by EUR 1,095 thousand in the first three months to EUR 4,578 thousand compared to EUR 5,674 thousand in the same period of the previous year. The gross margin decreased accordingly to 84% (prior-year period: 88%).

 

 

Biofrontera AG Quarterly report Q1 2021 3
 

 

Research and development costs

 

Research and development costs amounted to EUR 1,317 thousand in the first quarter and were flat compared to the prior-year amount of EUR 1,311 thousand. In addition to clinical trial expenses, research and development costs also include regulatory expenses, i.e. for the granting, maintenance and extension of our marketing authorizations.

 

General and administrative costs

 

General and administrative expenses amounted to EUR 2,538 thousand in the first quarter 2021, an increase of EUR 306 thousand or 14% compared to the prior-year period at EUR 2,232 thousand.

 

Sales and marketing costs

 

Sales and marketing expenses amounted to EUR 4,813 thousand, a decrease of EUR 3,885 thousand or 45% compared to the first quarter of 2020 at EUR 8,698 thousand. The decrease was mainly due to the impairment of the Xepi® license in the amount of EUR 2,001 thousand included in the prior-year figure, as well as the impact of the cost-saving measures introduced in 2020 due to the COVID-19 pandemic. Sales and marketing expenses mainly include the costs for our own sales force in Germany, Spain, the United Kingdom, and the United States as well as marketing expenses.

 

EBITDA and EBIT

 

In the 2021 financial year, EBITDA and EBIT have been introduced as key performance indicators for reporting purposes. Both have become established internationally as target metrics and will replace the previously reported key performance indicator profit/loss from operating activities.

 

Group EBITDA includes earnings before interest, taxes, depreciation of property, plant and equipment as well as amortization of intangible assets and decreased by EUR 513 thousand or 19% to a loss of EUR 3,158 thousand in Q1 2021 compared to a loss of EUR 2,645 thousand in the prior-year period.

 

EBIT includes earnings before interest and taxes and improved by 29% year-on-year to a loss of EUR 3,970 thousand compared to a loss of EUR 5,555 thousand in the prior-year period. This was due to higher depreciation and amortization in the previous year as a result of the unscheduled amortization of the Xepi® license.

 

Net interest result

 

Net interest result amounted to a loss of EUR 905 thousand (prior-year period: net interest profit of EUR 57 thousand) and, in addition to the interest expense for the EIB loan of EUR 483 thousand (prior-year period: EUR 431 thousand), also included the fair value changes of the purchase price liability for the acquisition of Cutanea Life Sciences, Inc. in the amount of EUR 328 thousand (prior-year period: income of EUR 341 thousand) as well as the performance component of the EIB loan in the amount of EUR 40 thousand (prior-year period: income of EUR 215 thousand).

 

Earnings before income tax

 

In the first three months of 2021, earnings before income taxes amounted to a loss of EUR 4,876 thousand, an improvement of EUR 622 thousand compared with the prior-year loss of EUR 5,498 thousand. This was mainly due to the amortization of the Xepi® license included in the prior-year figure, the effect of which offset the revenue development described above.

 

Biofrontera AG Quarterly report Q1 2021 4
 

 

Net assets of the Biofrontera Group

 

Total assets increased from EUR 56,391 thousand as of December 31, 2020 to EUR 77,076 thousand as of March 31, 2021. This was mainly due to the capital increase in February 2021 with gross proceeds of EUR 24.7 million.

 

The fully paid-in share capital of the parent company, Biofrontera AG, amounted to EUR 56,717 thousand as of March 31, 2021. It was divided into 56,717,385 ordinary registered shares with a nominal value of EUR 1.00 each. Total equity as of March 31, 2021 amounted to EUR 25,633 thousand compared to EUR 7,375 thousand as of December 31, 2020.

 

Financial position of the Biofrontera Group

 

Cash and cash equivalents amounted to EUR 37,333 thousand as of March 31, 2021, an increase of EUR 20,787 thousand compared to December 31, 2020, including the gross proceeds of EUR 24.7 million from the capital increase executed in February 2021. From today’s perspective, the Biofrontera Group thus has sufficient liquidity available in the upcoming 12 months to execute on the Group’s corporate strategy.

 

Outlook

 

Performance in the first quarter of 2021 was in line with the Management Board’s expectations. The Management Board therefore maintains its guidance for fiscal year 2021 published on April 12, 2021 in its entirety. Accordingly, the Management Board expects, among other things, annual revenue between EUR 25 and 32 million as well as EBITDA loss between EUR 11 and 14 million and EBIT loss between EUR 13 and 16 million. The detailed annual forecast is available in the Company’s Annual Report 2020, which is published on the website of Biofrontera AG at https://www.biofrontera.com/en/investors/financial-reports.

 

Biofrontera AG Quarterly report Q1 2021 5
 

 

Consolidated interim financial statements as of March 31, 2021

 

Assets

 

in EUR thousands  March 31, 2021   December 31, 2020 
   unaudited     
Non-current assets        
Tangible assets   4,778    5,051 
Intangible assets   18,012    17,688 
Deferred tax   7,525    7,525 
Total non-current assets   30,314    30,264 
           
Current assets          
Financial assets          
Trade receivables   2,484    3,501 
Other financial assets   718    531 
Cash and cash equivalents   37,333    16,546 
Total financial assets   40,535    20,579 
           
Other assets          
Inventories   4,962    4,673 
Income tax   0    5 
Other assets   1,264    869 
Total other assets   6,226    5,547 
           
Total current assets   46,762    26,126 
Total assets   77,076    56,391 

 

Biofrontera AG Quarterly report Q1 2021 6
 

 

Equity and liabilities

 

in EUR thousands  March 31, 2021   December 31, 2020 
   unaudited     
Equity        
Subscribed capital   56,717    47,748 
Capital reserve   137,248    123,493 
Capital reserve from foreign currency conversion adjustments   2,278    1,866 
Loss carried forward   (165,732)   (152,709)
Loss for the period   (4,877)   (13,023)
Total equity   25,633    7,375 
           
Non-current liabilities          
Financial debt   20,834    22,736 
Other financial liabilities   19,171    17,994 
Total non-current liabilities   40,005    40,730 
           
Current liabilities          
Financial liabilities          
Trade payables   2,697    1,623 
Current financial debt   3,145    1,139 
Other financial liabilities   79    90 
Total financial liabilities   5,920    2,852 
           
Other liabilities          
Other provisions   2,997    3,042 
Other current liabilities   2,521    2,392 
Total other liabilities   5,518    5,434 
           
Total current liabilities   11,438    8,286 

 

Biofrontera AG Quarterly report Q1 2021 7
 

 

Consolidated interim statements of comprehensive income for the three months ended March 31, 2021

 

in EUR thousands  Jan 1 – Mar 31, 2021   Jan 1 – Mar 31, 2020 
   unaudited   unaudited 
Sales revenue   5,479    6,473 
Cost of sales   (901)   (799)
Gross profit from sales   4,578    5,674 
           
Operating expenses          
Research and development costs   1,317    1,311 
General and administrative costs   2,538    2,232 
Sales and marketing costs   4,813    8,698 
Result from operations   (4,089)   (6,567)
           
Amortization and depreciation   813    2,911 
Other expenses   (101)   (7)
Other income   220    1,019 
EBITDA   (3,158)   (2,645)
Amortization and depreciation   -813    (2,911)
EBIT   (3,971)   (5,555)
Effective interest expenses   (95)   (72)
Interest expenses   (815)   (434)
Interest income   4    564 
           
Earnings (loss) before tax   (4,876)   (5,498)
Income tax   1    1 
Earnings (loss) after tax   (4,877)   (5,499)
           
Items which may in future be regrouped into the profit and loss statement under certain conditions.          
Translation differences resulting from the conversion of foreign business operations   (412)   (583)
Total result for the period   (5,289)   (6,082)
           
Basic and diluted earnings per share in EUR   (0.09)   (0.14)

 

Biofrontera AG Quarterly report Q1 2021 8

 

 EX-99.2 3 ex99-2.htm

 

Exhibit 99.2

 

 

 

Biofrontera reports Q1 2021 financial results

 

Leverkusen, Germany, May 11, 2021 – Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the first quarter ended March 31, 2021.

 

Q1 2021 key financial figures and business performance

 

In EUR thousands 

3M 2021

  

3M 2020

   Change 
Revenue   5,479    6,473    (15)%
Gross profit on sales   4,578    5,674    (19)%
Research and development costs   (1,317)   (1,311)   0%
General and administrative costs   (2,538)   (2,232)   14%
Sales and marketing costs   (4,813)   (8,698)   (45)%
Profit (loss) on operations   (4,089)   (6,567)   (38)%
EBITDA   (3,158)   (2,645)   19%
EBIT   (3,971)   (5,555)   (29)%
Earnings (loss) before tax   (4,876)   (5,498)   (11)%
Earnings (loss) after tax   (4,877)   (5,499)   (11)%

 

Biofrontera’s business performance was encouragingly positive after an initial, pandemic-related slow start at the beginning of the year. As expected, business activities and consequently sales continue to be heavily dependent on the development of the pandemic and the related easing of lockdown measures in our sales markets. While sales in the first quarter were 15% lower overall than in the same period of the previous year, the sales development since March shows a very positive trend,” summarizes Prof. Dr. Lübbert, CEO of Biofrontera. “This trend has continued into April 2021, indicating a stable recovery of the general pandemic situation in our sales markets, especially in the USA. April sales are also particularly encouraging when compared to 2019, i.e. monthly sales before the pandemic. Compared to that year, preliminary sales figures for April 2021 show an 8% increase in product sales in all markets. Compared to April 2019, April 2021 sales in the US increased by 3%, in Germany by 25% and in the remaining European markets by 20%.”

 

Sales of the Company for the period from January 1 to March 31, 2021, amounted to EUR 5,479 thousand, approximately 15% lower than revenues of EUR 6,473 thousand in the same period last year, whereby the current COVID-19 pandemic still had a major impact on business development, especially in the first two months.

 

 
 

 

In the U.S.A., the Company generated revenues from product sales of EUR 3,811 thousand in the first quarter, compared to EUR 4,181 thousand in the same period of the previous year, a decrease of 9%. While sales in the U.S.A. in January and February 2021 were, due to the pandemic, substantially lower than in the previous year, first quarter sales in Germany remained relatively stable compared to the previous year. Here, sales improved by 7% to EUR 1,404 thousand, compared to EUR 1,310 thousand in the first quarter of 2020. In the rest of Europe, sales decreased by 68% to EUR 265 thousand, compared to EUR 819 thousand in the first quarter last year.

 

Operating costs were 29% lower than in the prior-year quarter. In particular, sales and marketing expenses decreased by 45% compared to the first quarter of 2020. This was mainly due to the impairment of the Xepi® license in the amount of EUR 2,001 thousand included in the prior-year figure, as well as the impact of the cost-saving measures implemented in 2020 due to the COVID 19 pandemic.

 

Cash and cash equivalents amounted to EUR 37,333 thousand as of March 31, 2021, an increase of EUR 20,787 thousand compared to December 31, 2020, including the gross proceeds of EUR 24.7 million from the capital increase executed in February 2021. From today’s perspective, the Biofrontera Group thus has sufficient liquidity available in the upcoming 12 months to execute on the Group’s corporate strategy.

 

Outlook

 

Performance in the first quarter of 2021 was in line with the Management Board’s expectations. The Management Board therefore maintains its guidance for fiscal year 2021 published on April 12, 2021 in its entirety. Accordingly, the Management Board expects annual revenues between EUR 25 and 32 million as well as EBITDA loss between EUR 11 and 14 million and EBIT loss between EUR 13 and 16 million. The detailed annual forecast is available in the Company’s Annual Report 2020, which is published on the website of Biofrontera AG at https://www.biofrontera.com/en/investors/financial-reports.

 

Conference call

 

Conference calls for shareholders and interested investors will be held on Wednesday, May 12,

2021, at the following times:

 

In German, May 12, 2021 at 10:00 am CEST (4:00 am EST)

Dial-in number Germany: +49 69201744220

Conference code: 60386865#

 

In English, May 12, 2021 at 2:00 pm CEST (8:00 am EST)

Dial-in number USA: +1 8774230830

Dial-in number UK: +44 2030092470

Conference code: 52497289#

 

 
 

 

Please dial in 10 minutes ahead of time to ensure a timely start of the conference call.

 

Biofrontera AG’s quarterly report is available for download on the Company’s homepage at https://www.biofrontera.com/en/investors/financial-reports.

 

-End-

 

Biofrontera AG

Pamela Keck, Head of Investor Relations

ir@biofrontera.com

+49-214-87632-0

 

About Biofrontera:

 

Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.

 

The Germany-based company, with over 150 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company’s lead product is the combination of Ameluz®, a topical prescription drug, and medical device BF-RhodoLED® for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz® has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets the prescription medication Xepi® for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos®, which offers specialized care for damaged or diseased skin.

 

Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ.www.biofrontera.com.

 

Forward-looking statements: Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the public offering and the intended use of proceeds from the offering.

 

These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate” and “intend,” among others. Such forward-looking statements are based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and other factors are set forth in the Registration Statement on Form F-1 filed with the SEC, including in the section “Risk Factors,” and in future reports filed with the SEC. Given these risks, uncertainties and other factors, prospective investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake an obligation to update or revise any forward-looking statement.

 

 

 

 GRAPHIC 4 ex99-1_01.jpg begin 644 ex99-1_01.jpg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ex99-1_02.jpg begin 644 ex99-1_02.jpg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end GRAPHIC 6 ex99-2_001.jpg begin 644 ex99-2_001.jpg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